Transcode Therapeutics Inc (RNAZ)

Jun 11, 2026

TransCode Therapeutics (RNAZ) Rallies 3.27% as Biotech Stock Tests Key ResistanceFactor Crowding - newsline.com

Jun 11, 2026

Jun 10, 2026

RNAZ Technical Analysis & Stock Price Forecast - Intellectia AI

Jun 10, 2026

Jun 09, 2026

TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-Than-Expected Loss Amid No RevenueAnalyst Earnings Estimate - newsline.com

Jun 09, 2026

Jun 08, 2026

Daily Brief Health Care: Parabilis Medicines, Integral Diagnostics, Healthequity Inc, ICON PLC, KT Medical Service, Leong Guan Holdings, Oramed Pharmaceuticals , Otsuka Holdings, Crism Therapeutics, TransCode Therapeutics and more - Smartkarma

Jun 08, 2026

Jun 08, 2026

Inside a new colorectal cancer trial: TransCode’s June 18 webcast with Harvard oncologist - Stock Titan

Jun 08, 2026

Jun 08, 2026

RNAZ: Introducing RNA Therapeutics - Yahoo Finance

Jun 08, 2026

Jun 07, 2026

TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-Than-Expected Loss Amid Continued Pipeline DevelopmentMid-Term Outlook - newsline.com

Jun 07, 2026

Jun 05, 2026

RNAZ Q4 2024 Earnings: Wider-than-expected loss amid pre-revenue stageNet Profit Margin - newsline.com

Jun 05, 2026

Jun 04, 2026

Exclusive: TransCode's RNA therapeutic achieves 64% stable disease rate in colorectal cancer phase 1 study - MSN

Jun 04, 2026

Jun 03, 2026

TransCode Therapeutics (RNAZ) Advances to Phase 2a Following Pos - GuruFocus

Jun 03, 2026

Jun 03, 2026

RNAZ | TransCode Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative

Jun 03, 2026

Jun 03, 2026

TransCode Therapeutics Advances TTX-MC138 After Positive Phase 1a - TipRanks

Jun 03, 2026

Jun 03, 2026

TransCode completes phase 1a trial of cancer drug TTX-MC138 By Investing.com - Investing.com Australia

Jun 03, 2026

Jun 03, 2026

TransCode Therapeutics (RNAZ) sees clean Phase 1a safety, 64% stable disease with TTX-MC138 - Stock Titan

Jun 03, 2026

Jun 03, 2026

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer - PR Newswire

Jun 03, 2026

Jun 03, 2026

EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study - Benzinga

Jun 03, 2026

Jun 03, 2026

Cancer trial drug keeps tumors stable in 64% patients, without dose limits - Stock Titan

Jun 03, 2026

Jun 02, 2026

TransCode Therapeutics (RNAZ) proxy bundles big equity, financing and director votes - Stock Titan

Jun 02, 2026

Jun 01, 2026

TransCode Therapeutics sets date for 2026 annual meeting and proposal deadlines - Investing.com Nigeria

Jun 01, 2026

Jun 01, 2026

TransCode Sets Key Deadlines for 2026 Shareholder Meeting - TipRanks

Jun 01, 2026

Jun 01, 2026

TransCode Therapeutics, Inc. Files Form 8-K with NASDAQ Listing and Company Details (RNAZ) - Minichart

Jun 01, 2026

Jun 01, 2026

TransCode Therapeutics sets date for 2026 annual meeting and proposal deadlines By Investing.com - Investing.com South Africa

Jun 01, 2026

Jun 01, 2026

TransCode Therapeutics (RNAZ) sets July 2, 2026 annual meeting and June 11 proposal cutoff - Stock Titan

Jun 01, 2026

May 30, 2026

(RNAZ) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

May 30, 2026

May 29, 2026

RNAZ Stock Price, Quote & Chart | TRANSCODE THERAPEUTICS INC (NASDAQ:RNAZ) - ChartMill

May 29, 2026

May 27, 2026

TransCode Therapeutics Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease - citybuzz -

May 27, 2026

May 27, 2026

TransCode initiates phase 2a trial for colorectal cancer drug By Investing.com - Investing.com Australia

May 27, 2026

May 27, 2026

TransCode Therapeutics Initiates Phase 2a Clinical Trial With TTX-MC138 in Patients With CtDNA Positive Colorectal Cancer - Moomoo

May 27, 2026

May 26, 2026

TransCode Therapeutics (RNAZ) Drops 10.66%: Support at $5.3 Faces Critical Test After Sharp DeclineCTA Positioning - The Legal Advocate

May 26, 2026

May 26, 2026

TransCode Therapeutics Files 8-K/A Detailing Nasdaq Compliance Plan and Soliciting Material Disclosure - Minichart

May 26, 2026

May 26, 2026

Nasdaq warns TransCode (NASDAQ: RNAZ) on equity shortfall and delisting risk - Stock Titan

May 26, 2026

May 25, 2026

TransCode Therapeutics (RNAZ) Gains Over 2% as Biotech Stock Tests Key Resistance LevelsStop Hunt - newsline.com

May 25, 2026

May 22, 2026

TransCode Therapeutics Receives Nasdaq Listing Deficiency Notice - TipRanks

May 22, 2026

May 22, 2026

TransCode Therapeutics (RNAZ) Surges 2% as Biotech Stock Tests Key Resistance at $6.55Head and Shoulders - Newser

May 22, 2026

May 22, 2026

TransCode Therapeutics (NASDAQ: RNAZ) warned on Nasdaq equity shortfall - Stock Titan

May 22, 2026

May 20, 2026

[EFFECT] Transcode Therapeutics, Inc. SEC Filing - Stock Titan

May 20, 2026

May 17, 2026

What TransCode Therapeutics RNAZ flagged as biggest challenges ahead Q4 2024 Below ExpectationsEarnings Quality Score - newsline.com

May 17, 2026

May 15, 2026

TransCode Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 15, 2026

May 15, 2026

[10-Q] Transcode Therapeutics, Inc. Quarterly Earnings Report - Stock Titan

May 15, 2026

May 14, 2026

Mesa Air Group, Inc.Common Stock (NQ: MESA - FinancialContent

May 14, 2026

May 11, 2026

What you need to know before buying TransCode Therapeutics (RNAZ) (Breakdown Watch) 2026-05-11Fast Rising Picks - newser.com

May 11, 2026

May 10, 2026

What TransCode Therapeutics (RNAZ) flagged as biggest challenges ahead | Q4 2024: Below ExpectationsHigh Interest Stocks - newser.com

May 10, 2026

May 08, 2026

Trading Systems Reacting to (RNAZ) Volatility - Stock Traders Daily

May 08, 2026

May 08, 2026

TransCode Therapeutics (RNAZ) asks shareholders to OK preferred conversions, SEPA funding - Stock Titan

May 08, 2026

May 08, 2026

How TransCode Therapeutics (RNAZ) differentiates itself from competitors (Near Highs) 2026-05-08Open Stock Signal Network - newser.com

May 08, 2026

May 02, 2026

TransCode Therapeutics 2025 10-K/A: Executive Compensation, Board Members, and Corporate Governance Overview - Minichart

May 02, 2026

May 01, 2026

TransCode Registers 1.53 Million Shares for YA II PN Resale Under Equity Purchase Deal - marketscreener.com

May 01, 2026

Apr 30, 2026

TransCode Therapeutics (NASDAQ: RNAZ) registers 15.96M resale shares by selling holders - Stock Titan

Apr 30, 2026

Apr 30, 2026

TransCode Therapeutics (NASDAQ: RNAZ) updates 2025 governance, executive pay and ownership - Stock Titan

Apr 30, 2026

Apr 30, 2026

MSN Money - MSN

Apr 30, 2026

Apr 27, 2026

TransCode names Anna Moore scientific board chair - Investing.com UK

Apr 27, 2026

Apr 27, 2026

TransCode Therapeutics Appoints Dr. Anna Moore as Scientific Advisory Board Chair, Signs Research Agreement with Michigan State University - citybuzz -

Apr 27, 2026

Apr 27, 2026

TransCode names Anna Moore scientific board chair By Investing.com - Investing.com Australia

Apr 27, 2026

Apr 27, 2026

Transcode Therapeutics appoints Dr. Anna Moore as chair of scientific advisory board - marketscreener.com

Apr 27, 2026

Apr 27, 2026

TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University - PR Newswire

Apr 27, 2026

Apr 27, 2026

TransCode names co-founder Anna Moore chair, expands MSU research - Stock Titan

Apr 27, 2026